

BP-50621

Glofitamab Biosimilar – Anti-CD20/CD3 Bispecific Antibody

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).

Product Details	
Species Reactivity	Human
Source	Mammalian Cells
Isotype	IgG1-kappa/lambda with domain crossover, trivalent
Class	Anti-Human Bispecific antibodies
Type	Recombinant Humanized
Clone	NA
Target	Anti-human CD20/CD3
Purity	>99%
Molecular Weight	194 kDa
CAS Number	2229047-91-8
Formulation	NA
Storage conditions	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws Addition of 20 to 40 % glycerol may improve cryoprotection. Purified antibodies should ideally be stored as 0.5 to 2.0 mg/ml stock solutions. Aliquot the product according to your needs to avoid freeze/thaw cycles.